Table 3.
Clinical endpoints, by Cycle, ITT Analysis.
| Ciprofloxacin |
G-CSF |
|||||||
|---|---|---|---|---|---|---|---|---|
| Cycle | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| n (%) | 221 | 203 | 199 | 196 | 222 | 214 | 211 | 202 |
| Febrile Neutropenia | 23 (10.4) | 17 (8.4) | 9 (4.5) | 5 (2.6) | 10 (4.5) | 8 (3.7) | 4 (1.9) | 3 (1.5) |
| Treatment-related Hospitalisation | 25 (11.3) | 10 (4.9) | 4 (2.0) | 5 (2.6) | 15 (6.8) | 8 (3.7) | 7 (3.3) | 2 (1.0) |
| Chemotherapy dose reduction | 0 | 19 (9.4) | 12 (6.0) | 6 (3.1) | 0 | 18 (8.4) | 12 (5.7) | 9 (4.5) |
| Chemotherapy discontinuation | 18 (8.1) | 4 (2.0) | 3 (1.5) | 8 (4.1) | 8 (3.6) | 3 (1.4) | 5 (2.4) | 9 (4.5) |
| Chemotherapy dose delay | 0 | 9 (4.4) | 5 (2.5) | 2 (1.0) | 0 | 5 (2.3) | 9 (4.3) | 6 (3.0) |
| Microinfection | 5 (2.3) | 5 (2.5) | 2 (1.0) | 1 (0.5) | 6 (2.7) | 6 (2.8) | 1 (0.5) | 1 (0.5) |